Inhibrx Biosciences (INBX) Change in Accured Expenses (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Change in Accured Expenses data on file, last reported at -$1.4 million in Q4 2025.

• Change in Accured Expenses for Q4 2025 came in at -$1.4 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was -$4.4 million (down 112.15% YoY), and the FY2025 annual result was -$4.4 million, down 112.15% from the prior year.
• Change in Accured Expenses improved to -$1.4 million in Q4 2025 per INBX's latest filing, from -$1.5 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $21.8 million in Q2 2024 and troughed at -$4.3 million in Q2 2025.
• A 3-year average of $6.1 million and a median of $6.0 million in 2024 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses declined 5.05% in 2024, then sank 125.12% in 2025.
• A 3-year view of Change in Accured Expenses shows it stood at $17.4 million in 2023, then slumped by 65.33% to $6.0 million in 2024, then tumbled by 123.78% to -$1.4 million in 2025.
• Business Quant data shows INBX's Change in Accured Expenses at -$1.4 million in Q4 2025, -$1.5 million in Q3 2025, and -$4.3 million in Q2 2025.